Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.63 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.63 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | TGM2 | P21980 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.47 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1083120 | 1.00 | ZDHHC20 (0.63) | ZDHHC20ZDHHC2PRMT1ADRA1AMAPK1 | |
| SCHEMBL1018405 | 1.00 | ZDHHC20 (0.63) | ZDHHC20ZDHHC2PRMT1ADRA1AMAPK1 | |
| SCHEMBL1332462 | 1.00 | ZDHHC20 (0.63) | ZDHHC20ZDHHC2PRMT1ADRA1AMAPK1 | |
| SCHEMBL16229524 | 1.00 | ZDHHC20 (0.63) | ZDHHC20ZDHHC2PRMT1ADRA1AMAPK1 | |
| SCHEMBL1015381 | 1.00 | ZDHHC20 (0.63) | ZDHHC20ZDHHC2PRMT1ADRA1AMAPK1 | |
| SCHEMBL1334526 | 1.00 | ZDHHC20 (0.63) | ZDHHC20ZDHHC2PRMT1ADRA1AMAPK1 | |
| SCHEMBL15463341 | 1.00 | ZDHHC20 (0.63) | ZDHHC20ZDHHC2PRMT1ADRA1AMAPK1 | |
| SCHEMBL1018094 | 1.00 | ZDHHC20 (0.63) | ZDHHC20ZDHHC2PRMT1ADRA1AMAPK1 | |
| SCHEMBL707155 | 1.00 | ZDHHC20 (0.63) | ZDHHC20ZDHHC2PRMT1ADRA1AMAPK1 | |
| SCHEMBL1017486 | 1.00 | ZDHHC20 (0.63) | ZDHHC20ZDHHC2PRMT1ADRA1AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10119003-B2 | Surfactant-based monolithic columns, methods for making the same, and methods for using the same | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2018-11-06 | — | — | US | claimed |
| US-20130240358-A1 | Surfactant-Based Monolithic Columns, Methods for Making the Same, and Methods for Using the Same | Gergia State University Research Foundation, Inc. (US) | 2013-09-19 | — | — | US | claimed |
| US-20110086409-A1 | Surfactant-Based Monolithic Columns, Methods for Making the Same, and Method for Using the Same | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-04-14 | — | — | US | claimed |
| EP-2271602-A2 | SURFACTANT-BASED MONOLITHIC COLUMNS, METHODS FOR MAKING THE SAME, AND METHODS FOR USING THE SAME | Georgia State University Research Foundation, Inc. (US) | 2011-01-12 | — | — | EP | claimed |
| WO-2009151733-A2 | SURFACTANT-BASED MONOLITHIC COLUMNS, METHODS FOR MAKING THE SAME, AND METHODS FOR USING THE SAME | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2009-12-17 | — | — | WO | claimed |
| WO-2009054609-A1 | BONE REGENERATION MEMBRANE AND METHOD FOR MANUFACTURING BONE REGENERATION MEMBRANE | MEGAGEN IMPLANT CO., LTD. (KR) | 2009-04-30 | — | — | WO | claimed |
| WO-2007123495-A1 | METHOD OF PATTERNING AND PRODUCT(S) OBTAINED THEREFROM | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2007-11-01 | — | — | WO | claimed |
| US-10919926-B2 | Compound or salt thereof, natural killer T cell activator, and pharmaceutical composition | KEIO UNIVERSITY (JP) | 2021-02-16 | — | — | US | disclosed |
| US-10919926-B2 | Compound or salt thereof, natural killer T cell activator, and pharmaceutical composition | KEIO UNIVERSITY (JP) | 2021-02-16 | — | — | US | disclosed |
| US-20200207798-A1 | COMPOUND OR SALT THEREOF, NATURAL KILLER T CELL ACTIVATOR, AND PHARMACEUTICAL COMPOSITION | KEIO UNIVERSITY (JP) | 2020-07-02 | — | — | US | disclosed |
| US-20200207798-A1 | COMPOUND OR SALT THEREOF, NATURAL KILLER T CELL ACTIVATOR, AND PHARMACEUTICAL COMPOSITION | KEIO UNIVERSITY (JP) | 2020-07-02 | — | — | US | disclosed |
| EP-3502755-A1 | DISPLAY MEDIUM FOR ASSESSMENT AND METHOD FOR MANUFACTURING SAME | Zeon Corporation (JP) | 2019-06-26 | — | — | EP | disclosed |
| EP-3434684-A1 | COMPOUND OR SALT THEREOF, NATURAL KILLER T CELL ACTIVATOR, AND PHARMACEUTICAL COMPOSITION | Keio University (JP) | 2019-01-30 | — | — | EP | disclosed |
| US-20090088343-A1 | METHOD OF PATTERNING AND PRODUCT(S) OBTAINED THEREFROM | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2009-04-02 | — | — | US | disclosed |
| US-20080281014-A1 | Nanosubstance-Containing Composition, Process for Producing the Same, and Composite Made With the Same | MITSUBISHI RAYON CO., LTD. (JP) | 2008-11-13 | — | — | US | disclosed |
| WO-2007123495-A1 | METHOD OF PATTERNING AND PRODUCT(S) OBTAINED THEREFROM | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2007-11-01 | — | — | WO | disclosed |
| CN-101001912-A | Nanosubstance-containing composition, method for producing same, and composite using same | MITSUBISHI RAYON CO (JP) | 2007-07-18 | — | — | CN | disclosed |
| EP-0181528-B1 | ABRASION-RESISTANT ULTRAVIOLET-CURABLE COATINGS | DeSOTO, INC. (US) | 1988-04-20 | — | — | EP | disclosed |
| US-4600649-A | Abrasion-resistant ultraviolet-curable coatings | DESOTO, INC. (US) | 1986-07-15 | — | — | US | disclosed |
| EP-0181528-A1 | Abrasion-resistant ultraviolet-curable coatings | DeSOTO, INC. (US) | 1986-05-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086409-A1 | Surfactant-Based Monolithic Columns, Methods for Making the Same, and Method for Using the Same | PORCN, STOM, SMURF1 | ZDHHC20 759/4885ZDHHC2 271/4885PRMT1 2382/4885 |
| US-20200207798-A1 | COMPOUND OR SALT THEREOF, NATURAL KILLER T CELL ACTIVATOR, AND PHARMACEUTICAL COMPOSITION | CD4, NFATC1, PBK | ZDHHC20 567/4885ZDHHC2 1093/4885PRMT1 2389/4885 |
| US-10919926-B2 | Compound or salt thereof, natural killer T cell activator, and pharmaceutical composition | CD4, NFATC1, PBK | ZDHHC20 722/4885ZDHHC2 1333/4885PRMT1 2109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.